Orthofix Medical Inc (OFIX)

Currency in USD
7.180
+0.060(+0.84%)
Closed·
7.160-0.020(-0.28%)
·
OFIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.9407.400
52 wk Range
6.52016.420
Key Statistics
Prev. Close
7.18
Open
7.02
Day's Range
6.94-7.4
52 wk Range
6.52-16.42
Volume
763.52K
Average Volume (3m)
453.86K
1-Year Change
-53.0719%
Book Value / Share
10.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OFIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.000
Upside
+39.28%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Orthofix Medical Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 10.000
(+39.28% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Hold9.00+25.35%12.00Maintain10-11-2026
Canaccord
Buy11.00+53.20%13.00Maintain10-11-2026
Stifel
Buy13.00+81.06%-Maintain15-09-2026
Canaccord
Buy13.00+81.06%18.00Maintain10-08-2026
Stifel
Buy13.00+81.06%15.00Maintain05-08-2026

Orthofix Medical Inc SWOT Analysis


Financial Resilience
Orthofix outperforms expectations in Q1 2025, showcasing strong operational efficiency despite strategic changes and market challenges
Strategic Repositioning
Delve into Orthofix's transition phase, including the M6 disc phase-out and new credit agreement, shaping its long-term growth trajectory
Product Innovation
Explore Orthofix's expanding portfolio, featuring early FDA approval for AccelStim 2.0 and new spine and ortho products, driving market position
Growth Projections
Analysts maintain a Market Perform outlook, with Orthofix targeting 6-7% top-line CAGR through 2027 and mid-teens adjusted EBITDA
Read full SWOT analysis

Orthofix Medical Inc Earnings Call Summary for Q3/2026

  • Orthofix Q3 beat EPS estimates at -$0.15 vs -$0.27 expected, but missed revenue at $207.9M vs $210.7M; shares plunged 15.25% to $6.67.
  • U.S. spine fixation fell 5% YoY due to market softness and supplier delays; Limb Reconstruction rose 9% constant-currency, offsetting weakness.
  • Full-year 2026 guidance cut to $825M-$830M revenue and $86M-$88M adjusted EBITDA, citing spine headwinds and FX pressure.
  • CEO Calafiore outlined recovery plan focusing on top partners and high-value tech; supply issues expected resolved by Q4 2026 end.
  • 2027 outlook includes VIRATA launch benefit in Q1, but faces $22M European MDR timing headwind; core revenue expected positive ex-MDR impact.
Last Updated: 09-11-2026, 07:42 pm
Read Full Transcript

Earnings

Latest Release
09-11-2026
EPS / Forecast
-0.15 / -0.27
Revenue / Forecast
207.86M / 210.69M
EPS Revisions
Last 90 days

OFIX Income Statement

Compare OFIX to Peers and Sector

Metrics to compare
OFIX
Peers
Sector
Relationship
P/E Ratio
−6.5x−15.0x−0.2x
PEG Ratio
−0.09−0.510.00
Price/Book
0.7x4.3x2.6x
Price / LTM Sales
0.4x2.2x2.8x
Upside (Analyst Target)
39.3%48.9%60.5%
Fair Value Upside
Unlock−14.7%7.8%Unlock

Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
9.53M23.39%75.28M
Other Institutional Investors
41.17M76.61%325.23M
Public Companies & Retail Investors
0.000.00%0.00
Total
50.7M100.00%400.51M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Juniper Investment Company, LLC11.76%47,92,04337,857
Engine Capital Management, LP11.23%45,75,67536,148

FAQ

What Is the Orthofix (OFIX) Share Price Today?

The Orthofix share price today is 7.180.

What is the current Orthofix (OFIX) share price and day range?

As of 12-11-2026, the Orthofix share price is 7.180, with a previous close of 7.180. The share price has ranged from 6.940 to 7.400 today, while the 52-week range spans from 6.520 to 16.420.

What Is the Orthofix Market Cap?

As of today, Orthofix market cap is 292.660M.

What Is the Orthofix (OFIX) Share Price Target?

The average 12-month share price target for Orthofix is 10.000, with a high estimate of 11 and a low estimate of 9. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +39.28% Upside potential.

What Is Orthofix's Earnings Per Share (TTM)?

The Orthofix EPS (TTM) is -1.11.

When Is the Next Orthofix Earnings Date?

Orthofix will release its next earnings report on 19-02-2027.

From a Technical Analysis Perspective, Is OFIX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Orthofix Trade On?

Orthofix is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Orthofix?

The stock symbol for Orthofix is "OFIX."

How Many Times Has Orthofix Stock Split?

Orthofix has split 0 times.

How Many Employees Does Orthofix Have?

Orthofix has 1605 employees.

What Is the OFIX After Hours Price?

OFIX's last after hours stock price is 7.160, the stock has changed by -0.020, or -0.280%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.